Literature DB >> 16557730

Immunosuppression by murine sarcoma virus (Moloney).

S P Chan1, W A Hook, W Turner, M A Chirigos.   

Abstract

Infection of mice with the murine sarcoma virus (Moloney) markedly suppressed the humoral antibody response to sheep erythrocyte antigen injected 10 days after infection, when tumor size was maximal, and on day 26, when primary tumors had partially regressed. Humoral antibody response was also inhibited when antigen was injected at the time secondary tumors and metastases were evident. No significant suppression of humoral antibody was seen when mice were injected with sheep erythrocyte antigen 5 days after virus infection. Inhibition of the cellular immune response of murine sarcoma virus (Moloney)-infected mice, as measured by the increased survival time of skin grafts, was also determined. Mice that were infected 5 days prior to grafting demonstrated prolonged survival of grafts, suggesting a suppression of cellular immunity. These mice had a graft survival time 14 days greater than noninfected controls. No significant prolongation of graft survival was seen in mice grafted at the times of maximum primary tumor growth, of primary tumor regression, or when secondary tumors had appeared.

Entities:  

Year:  1970        PMID: 16557730      PMCID: PMC415894          DOI: 10.1128/iai.1.3.288-292.1970

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  19 in total

1.  A DEFECT IN CELLULAR IMMUNITY DURING THE INCUBATION PERIOD OF PASSAGE A LEUKEMIA IN C3H MICE.

Authors:  P B DENT; R D PETERSON; R A GOOD
Journal:  Proc Soc Exp Biol Med       Date:  1965-07

2.  Decreased rate of synthesis of immunoglobulin (IgG) in rats infected with moloney leukemia virus.

Authors:  S F Cure; N E Cremer
Journal:  J Immunol       Date:  1969-06       Impact factor: 5.422

3.  Immunosuppressive effects of Friend and Rauscher leukemia disease viruses on cellular and humoral antibody formation.

Authors:  W S Ceglowski; H Friedman
Journal:  J Natl Cancer Inst       Date:  1968-05       Impact factor: 13.506

4.  Increased tumorigenesis of murine sarcoma virus (Moloney) by coinfection with Rauscher virus or by treatment with antilymphocyte serum.

Authors:  W A Hook; M A Chirigos; S P Chan
Journal:  Cancer Res       Date:  1969-05       Impact factor: 12.701

5.  Quantitative dose-response relationships of murine sarcoma virus (Moloney) in BALB/c mice.

Authors:  G R Blumenschein; J B Moloney
Journal:  J Natl Cancer Inst       Date:  1969-01       Impact factor: 13.506

6.  Immunosuppression by leukemia viruses. 3. Adoptive transfer of antibody-forming cells to Friend disease virus-infected mice.

Authors:  W S Ceglowski; H Friedman
Journal:  J Immunol       Date:  1969-09       Impact factor: 5.422

7.  The suppressive effect of Rauscher leukemia virus on the secondary antibody response of spleen cells cultured in cell-impermeable diffusion chambers.

Authors:  L Borella
Journal:  J Immunol       Date:  1969-08       Impact factor: 5.422

8.  Antibody formation, latency and leukemia: infection with Moloney virus.

Authors:  N E Cremer; D O Taylor; S J Hagens
Journal:  J Immunol       Date:  1966-03       Impact factor: 5.422

9.  Serum agglutinin levels to sheep red blood cells in mice infected with Rauscher virus.

Authors:  B V Siegel; J I Morton
Journal:  Proc Soc Exp Biol Med       Date:  1966-11

10.  Titration patterns of a murine sarcoma-leukemia virus complex: evidence for existence of competent sarcoma virions.

Authors:  T E O'Connor; P J Fischinger
Journal:  Science       Date:  1968-01-19       Impact factor: 47.728

View more
  2 in total

1.  Submandibular gland-conditioned medium enhancement of bone marrow colony-forming cells in tumor-bearing murine recipients.

Authors:  D F Gruber; G D Ledney
Journal:  Experientia       Date:  1983-01-15

2.  Tumor induction by murine sarcoma virus in AKR and C58 mice. Reduction of tumor regression associated with appearance of Gross leukemia virus pseudotypes.

Authors:  L Chieco-Bianchi; A Colombatti; D Collavo; F Sendo; T Aoki; P J Fischinger
Journal:  J Exp Med       Date:  1974-11-01       Impact factor: 14.307

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.